02 May 2003
Camptothecin induced topoisomerase I-DNA complexes are targeted and reversed by poly(ADP-ribose)
M. Malanga, O. Cohausz, F. AlthausMed Sci Monit 2003; 9(1): 38-0 :: ID: 15101
Abstract
Camptothecin (CPT) and its clinically used congeners base their potency as anticancer drugs on the ability to stabilize topoisomerase I-cleaved DNA covalent complexes; such long-lived nucleoprotein complexes constitute a challenge to genomic integrity and cell viability as they can be converted in potentially lethal DNA damage upon collision with replication/transcription machineries [1]. Many DNA structural lesions have been shown to have a similar ‘poisoning’ effect [2]. The observation that PARP inhibitors potentiate the cytotoxicity of CPT in irradiated cells [3] suggests a correlation between poly(ADP-ribose) synthesis and cell’s ability to cope with topoisomerase I-induced DNA damage. Using an in vitro system we investigated whether the steady state level of topoisomerase I-DNA complexes could be modulated by poly(ADP-ribosyl)ation. We observed that both PARP-1 and PARP-2 in their automodified form reduced topoisomerase I-DNA covalent complexes, while they had little or no effect in their native state. The decrease in the number of nucleoprotein complexes occurred even in the presence of CPT and appeared to be specifically dependent on, and proportional to, the amount of PARP-bound poly(ADP-ribose). We found that poly(ADP-ribose) interacts noncovalently with topoisomerase I and identified two binding motifs at critical sites for the enzyme activity. Further experiments revealed that topoisomerase I in covalent complex with its substrate was a preferred target for poly(ADP-ribose). Such specific targeting resulted in a complete reversion of the cleavage complexes, in spite of the stabilizing effect of CPT. Work is in progress to evaluate the occurrence of such poly(ADP-ribose)-mediated repair of topoisomerase I-DNA covalent complexes in living cells. References: 1.Kohn KW, Pommier Y: Annals NY Acad Sci, 2000; 922: 11-26 2.Pourquier P, Waltman JL, Urasaki Y et al: Cancer Res, 2001; 61: 53-58 3.Bowman KJ, Newell DR, Calvert AH, Curtin NJ: Br J Cancer, 2001; 84: 106-112
Keywords: PARP-2, noncovalent interactions, DNA Repair
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952